Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Ra Pharmaceuticals
Age
18–85
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Diagnosis of gMG \[Myasthenia Gravis Foundation of America (MGFA) Class II-IVa\] at Screening
Positive serology for acetylcholine receptor (AChR) autoantibodies
QMG score ≥ 12 at Screening and Randomization
No change in corticosteroid dose for at least 30 days prior to Randomization or anticipated to occur during the 12-week Treatment Period
No change in immunosuppressive therapy, including dose, for at least 30 days prior to Randomization or anticipated to occur during the 12-week Treatment Period
You may not be if
Thymectomy within 6 months prior to Randomization or scheduled to occur during the 12 week Treatment Period
History of meningococcal disease
Current or recent systemic infection within 2 weeks prior to Randomization or infection requiring intravenous (IV) antibiotics within 4 weeks prior to Randomization
Clareo Health | Safety and Efficacy Study of RA101495 in Subjects With Generalized Myasthenia Gravis
